We describe two methods for the quantitative analysis of apalcillin and its metabolites in serum and urine by reverse-phase high-pressure liquid chromatography (HPLC), a fast isocratic method for the parent drug, and a gradient method that allows the simultaneous assay of two metabolites. Serum was deproteinized with acetonitrile, and urine was diluted with buffer solution. The detection limit was about 0.5 jg/ml at a detection wavelength of 254 nm and 1.5 ,ug/ml at 310 nm.
0.992 XHPLC, and that for urine was Ybioassay = 12.0 ,ug/ml + 1.009 * XHPLC. At a detection wavelength of 315 nm, no interferences were observed in 10 healthy volunteers. Healthy subjects who were given 2 g of apalcillin intravenously excreted 18% of the parent drug within 24 h in the urine. Two inactive compounds were furthermore identified in urine as the isomeric forms of the penicilloic acids. Their excretion within 24 h amounted to 6.9 and 11.2% of the dose.
Apalcillin (sodium(2S, 5R, 6R)-6-[(R)-2-(4-hydroxy -1,5 -naphthyridine -3 -carboxamido-) -2 -phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane -2 -carboxylate) was developed by N. Noguchi et al. (3) . It has a high in vitro antimicrobial activity against Pseudomonas aeruginosa and other gram-negative bacteria. This property is attributed to the naphthyridine-carboxamido side chain (2) . Preliminary studies on its pharmacokinetics show poor intestinal absorption, a high serum protein binding rate (98%), and a high biliary excretion in rats (2) . For our studies on the pharmacokinetics of apalcillin in humans, we Fig. 2 . The isocratic method is simple, fast, and suitable for assay of the parent drug in both serum and urine. The separation of metabolites that contain additional ionic groups (Fig. 3) requires the application of a gradient method as described in Materials and Methods. Typical separation patterns of urine specimens are shown in Fig. 4 Precision, accuracy, and identification of peaks. Within-batch precision was measured by using pooled sera in three concentrations (7.8, 32.8, and 185.3 ,ug/ml), each in 10 replicates. Coefficients of variation were 10.2, 5.2, and 1.1%. Recovery rates for the drug added to serum pools were 95.1% (100 p,g/ml) and 97.7% (200 ,g/ml). The average percent recovery of drug added to blank sera of 10 healthy subjects was 99.0%.
The presence of apalcillin in serum and urine was confirmed by enzymatic degradation with beta-lactamase type II from Bacillus cereus (EC.3.5.2.8), which resulted in a complete disappearance of the apalcillin peak. Concomitantly, the peak of metabolite Al in urine increased.
In another experiment, a large urine specimen (100 ,lI) from a 0-to 3-h period was chromatographed by the gradient method at a reduced flow rate. One-milliliter fractions of the eluate were collected. UV spectra of the fractions (cf. Fig. 4C ) revealed three peaks, the spectrum of the naphthyridine group being typical. Both apalcillin and the metabolite Al yielded identical retention times when pure reference material was chromatographed (Fig. 4A and B) . The peak AX is most likely the isomer A2 of metabolite Al which, according to the internal data of the manufacturer, is formed spontaneously from Al in an aqueous solution at 40°C. Method comparison and interferences. Bioassay and HPLC showed good correlations for serum (Fig. 5) and urine (Fig. 6 ). It should be noted, however, that in using a 254-nm wavelength for detection, one may encounter interferences from caffeine and its metabolites at low concentrations of apalcillin. Therefore, the' use of a 310-nm wavelength for detection is preferred, with which interferences from other substances are less likely to occur.
The chromatographic behavior of several endogenous substances and other antibiotics and drugs is shown in Table 1 .
Renal excretion of apalcilhin and its metabolites. Ten healthy subjects were given a single intravenous dose of 2 g of apalcillin. The average recovery from 24-h urine specimens was 18.3% for apalcillin, 6.9%o for metabolite Al, and 11.2% for metabolite A2. DISCUSSION Only 18% of intravenously administered apalcillin could be recovered from 24-h urine specimens of healthy volunteers when a conventional bioassay was used. This result prompted us to develop an alternative assay method that might confirm this result and give additional quantitative information on the excretion of metabolites.
In developing a suitable HPLC method, we had to take into consideration the UV spectra of the substances to be analyzed (Fig. 1) , the influence of pH on their polarity and stability during chromatography and in a prior deproteinization step, and possible interferences by en- The addition of the acidic buffer 3.15 reduces the stability of the analyte. Therefore, the final dilution step should be followed by chromatography as soon as possible. The packing of the column showed fair but variable stability, requiring frequent replacements when large numbers of samples were to be analyzed. The gradient method also separated the more polar metabolites (Fig. 4) . Its main disadvantage was a threefold-longer run time as compared with the isocratic method.
The presence of the parent drug in serum and urine chromatograms was confirmed by treatment with beta-lactamase and by the UV spectrum of the drug isolated from urine. The good correlation of results from bioassay and from HPLC also supports this identification. Another two peaks were observed in the urine of 10 volunteers after a single dose of the drug. They were tentatively called Al and AX. Both compounds yield, upon isolation from urine, qualitatively identical UV spectra as compared with apalcillin. Al has the same retention time as a reference substance which also contains a minor impurity appearing at the retention time of AX. From physical degradation studies (unpublished data), it is likely that AX is the isomer A2 which differs from Al only by the position of the hydrogen atom at position 5S (cf. Fig. 1 ).
